Biomarkers of Medication Exposure Variability During Pharmacy-Led Care Transitions

Abstract

Medication exposure variability is a significant concern during care transitions, often leading to adverse drug events and suboptimal clinical outcomes. Pharmacy-led interventions have emerged as critical components in mitigating these risks. This review explores the evolving landscape of biomarkers utilized to monitor medication exposure variability in the context of pharmacy-led care transitions, integrating recent evidence, mechanistic insights, and guideline-based recommendations. The article examines the epidemiology, pathophysiology, risk factors, clinical features, diagnostic strategies, current management approaches, emerging therapies, and expert guidelines, providing clinicians with a comprehensive view to optimize patient safety and therapeutic outcomes.

Introduction

Transitions of care, particularly from hospital to community settings, represent vulnerable periods for patients, where medication errors and adverse drug events (ADEs) are prevalent. Pharmacy-led care transition programs have demonstrated efficacy in reducing medication discrepancies, improving adherence, and enhancing clinical outcomes. However, variability in medication exposure owing to factors such as pharmacokinetics, pharmacodynamics, adherence, and patient-specific variables remains a challenge. The identification and application of objective biomarkers to quantify and monitor this variability during pharmacy-led transitions is an emerging and highly relevant field, promising to personalize pharmacotherapy and enhance patient safety.

Epidemiology / Disease Burden

Medication errors during care transitions contribute to a substantial proportion of preventable hospital readmissions and healthcare costs worldwide. Studies indicate that up to 60% of patients experience medication discrepancies upon hospital discharge, with ADEs occurring in approximately 20% of patients within 30 days post-discharge. Polypharmacy, complex regimens, and fragmented communication between healthcare providers exacerbate the risk. The burden is particularly high among elderly patients and those with multiple comorbidities, underscoring the need for robust strategies to monitor and address medication exposure variability.

Pathophysiology

The pathophysiology of medication exposure variability is multifactorial. Variability arises from differences in drug absorption, distribution, metabolism, and excretion (ADME), influenced by genetic polymorphisms, organ function, drug-drug interactions, and patient adherence. During care transitions, abrupt changes in medication regimens, incomplete handover of clinical information, and inconsistent follow-up further disrupt pharmacotherapeutic stability. Biomarkers ranging from pharmacokinetic measures (e.g., plasma drug concentrations) to pharmacodynamic indices (e.g., target engagement markers) and adherence indicators (e.g., metabolite levels) offer mechanistic insights into the sources and impact of this variability.

Risk Factors

Key risk factors for medication exposure variability during care transitions include advanced age, renal or hepatic impairment, polypharmacy, use of high-risk medications (e.g., anticoagulants, antiepileptics, immunosuppressants), cognitive impairment, low health literacy, and inadequate communication between healthcare providers. Social determinants such as limited access to pharmacies, financial constraints, and lack of caregiver support also play a significant role. Identifying these risk factors enables targeted interventions and the strategic deployment of biomarker monitoring.

Clinical Features

Clinically, medication exposure variability may manifest as therapeutic failure, toxicity, or adverse drug reactions. Symptoms can range from subtle biochemical abnormalities to overt clinical deterioration, such as uncontrolled hypertension, seizures, bleeding, or organ dysfunction. In many cases, the variability is subclinical, detectable only through biomarker surveillance. Recognizing early warning signs and correlating them with objective measures is critical for timely intervention in pharmacy-led care transitions.

Diagnosis

Diagnosis of medication exposure variability relies increasingly on biomarker assays. Pharmacokinetic biomarkers, such as plasma or serum drug concentrations (e.g., vancomycin, tacrolimus), are routinely employed in therapeutic drug monitoring (TDM). Pharmacodynamic biomarkers, including INR for warfarin or platelet function tests for antiplatelet agents, provide functional readouts of drug activity. Adherence biomarkers, such as urine or blood metabolite panels, help differentiate true pharmacologic variability from non-adherence. The integration of pharmacogenomic data further refines diagnostic accuracy, enabling personalized risk stratification during care transitions.

Treatment & Management

Pharmacy-led interventions are central to managing medication exposure variability. Comprehensive medication reconciliation, patient counseling, and post-discharge follow-up are foundational strategies. Incorporating biomarker data enhances these interventions by allowing real-time adjustments to dosing, monitoring for toxicity, and ensuring therapeutic efficacy. Clinical pharmacists, in collaboration with physicians, utilize TDM protocols and adherence biomarker results to individualize therapy. Educational initiatives and digital health tools, such as mobile apps for reminder and monitoring, augment traditional care approaches.

Recent Advances / Emerging Therapies

Recent advances have expanded the utility of biomarkers in pharmacy-led care transitions. Novel point-of-care assays, wearable biosensors, and remote monitoring platforms enable continuous assessment of drug exposure and adherence. Multiplexed biomarker panels, integrating pharmacokinetic, pharmacodynamic, and pharmacogenomic data, offer a holistic view of patient-specific medication profiles. Machine learning algorithms are being developed to predict variability and guide proactive interventions. Ongoing research focuses on validating new biomarkers for commonly used but high-risk medications, with the aim of integrating these tools into routine transitional care workflows.

Guideline Recommendations

International guidelines, including those from the Institute for Safe Medication Practices (ISMP) and the American Society of Health-System Pharmacists (ASHP), emphasize the importance of pharmacy-led care transitions and the role of biomarkers in optimizing medication safety. Recommendations include systematic medication reconciliation, risk stratification using clinical and biomarker data, and the adoption of TDM for drugs with narrow therapeutic windows. Pharmacogenomic screening is increasingly advocated for high-risk populations. Guidelines highlight the need for interprofessional collaboration and the integration of digital health tools to facilitate biomarker-driven care.

Conclusion

Biomarkers of medication exposure variability represent a transformative advancement in pharmacy-led care transitions, enabling clinicians to detect and address risk factors for adverse drug events proactively. By integrating objective biomarker data with comprehensive pharmacy-led interventions, healthcare teams can personalize pharmacotherapy, improve patient outcomes, and reduce the burden of medication-related harm during vulnerable care transitions. Ongoing research and technological innovation will continue to expand the clinical utility of biomarkers, reinforcing their central role in the future of medication management and patient safety.